Lonza clarified its reported position, inPharma Technologist, with regard to its joint venture with Teva. A recent interview with Lonza's CEO had led writers to imply that Lonza was rethinking its position on biosimilars -- and presumably its JV with Teva to produce biosimilar drugs. This was largely caused (according to these articles) by FDAs less than clear guidance on a biosimilar pathway, and the resultant uncertainty to the biosimilar economic models that had been developed circa 2009.
Lonza moved o quash this notion today by reaffirming its intent to produce biosimilars as stated previously thorugh the Teva connection. Lonza will however review its assumptions around the economic models for biosimilars -- particularly in the US market.
"Biosimilars remain an attractive market opportunity and both parties stay fully committed to the TL collaboration," said a Lonza spokesman.
Posted by Bruce Lehr Apr 3rd 2013.